Advancements in antimalarial drug discovery and development

In partnership with:

Now available on-demand

Overview:

This session highlights recent innovations and practical strategies in antimalarial drug discovery, including advanced screening techniques, novel compound development, and data-driven decision-making across the R&D pipeline. Gain insights into how mechanistic understanding of parasite resistance and optimization of pharmacokinetic parameters are accelerating candidate selection and enhancing therapeutic efficacy.

What you will learn:

• Explore the strengths and applications of phenotypic vs. target-based screening in antimalarial drug discovery.
• Learn how structure-activity relationship (SAR) optimization drives the development of more effective compounds.
• Understand the molecular mechanisms behind next-generation antimalarial agents.
• Discover strategic approaches to overcoming and mitigating parasite drug resistance.

Speakers:

Gang Liu, Ph.D.
Senior Program Officer
Gates Foundation

Brice Campo, Ph.D.
Head of Biology and Innovative Technologies
Medicines for Malaria Venture

James Duffy, Ph.D.
Senior Director of Drug Discovery
Medicines for Malaria Venture

Jeremy Burrows, Ph.D.
VP, Head of Discovery
Medicines for Malaria Venture

Dominique Besson, MBA
Associate Director of Discovery Data & Alliance Management
Medicines for Malaria Venture

Kelly Chibale, Ph.D.
Professor of Organic Chemistry
University of Cape Town

Elizabeth Winzeler, Ph.D.
Associate Dean and Professor
University of California, San Diego

Mariana Vaschetto, Ph.D.
Director Of Operations EMEA-AP-LATAM
Collaborative Drug Discovery

Dylan Kissane
Host and Director of Editorial
Labiotech